MARKET

PLX

PLX

Protalix Biother
AMEX
2.890
-0.020
-0.69%
After Hours: 2.870 -0.02 -0.69% 19:36 02/06 EST
OPEN
2.890
PREV CLOSE
2.910
HIGH
2.930
LOW
2.780
VOLUME
2.56M
TURNOVER
--
52 WEEK HIGH
3.100
52 WEEK LOW
1.320
MARKET CAP
232.42M
P/E (TTM)
62.69
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 4d ago
Weekly Report: what happened at PLX last week (0126-0130)?
Weekly Report · 6d ago
A March Decision That Could Change Protalix BioTherapeutics Outlook
Seeking Alpha · 6d ago
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy
Seeking Alpha · 01/30 17:53
Protalix Wins EMA Panel Backing for New Elfabrio Dosing
TipRanks · 01/30 15:28
Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing
TipRanks · 01/30 14:56
Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment
Benzinga · 01/30 14:51
Weekly Report: what happened at PLX last week (0119-0123)?
Weekly Report · 01/26 09:38
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Webull offers Protalix Biotherapeutics Inc stock information, including AMEX: PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.